TIDMFARN
RNS Number : 1996U
Faron Pharmaceuticals Oy
24 March 2023
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Board Change
Company announcement, March 24, 2023 at 15.35 PM (EET) / 13.35
PM (GMT) / 09.35 AM (EDT)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM:
FARN, First North: FARON), a clinical stage biopharmaceutical
company focused on tackling difficult-to-treat cancers, is pleased
to announce the appointment of Mr. Tuomo Pätsi as a Non-Executive
Director of the Company following the passing of all resolutions
put to shareholders of the Company at the Annual General Meeting
held earlier today. In addition, Dr. Gregory B. Brown has today
stepped down from his position as a Non-Executive Director of the
Company.
"I am pleased to welcome Mr Pätsi to the Faron Board," said Dr.
Frank Armstrong, Chairman of the Board of Faron Pharmaceuticals.
"He brings extensive experience of the commercialization and launch
of new oncology products with leading cancer companies, and his
expertise will be valuable as the Company continues the development
of bexmarilimab. I'd also like to thank Dr. Brown for his service
to the Faron Board."
Mr. Pätsi was the President of the EMEA region and Worldwide
Markets for Celgene Corporation, a global pharmaceutical company
and currently wholly owned subsidiary of Bristol Myers Squibb,
engaged primarily in the discovery, development and
commercialization of therapies for the treatment of cancer. He is
an experienced biotech and pharmaceutical executive who was until
recently the Executive Vice President for Seagen Inc., a US-based
cancer-focused biotechnology company.
"I am looking forward to joining the Board of Faron at this
exciting time," said Mr Pätsi. "Bexmarilimab with its innovative
mechanism of action and clinical data so far holds great promise in
multiple cancer indications where better treatments are desperately
needed."
Mr. Pätsi has over 30 years' experience working in biotech and
pharmaceuticals, with more than 10 years working at Celgene in
various senior management roles, including as President of European
and International Operations and President of the EMEA region and
Worldwide Markets. Prior to this, he served as Vice President of
Europe for Human Genome Science, a specialty pharma organization in
Europe. Earlier in his career, he held roles of increasing
responsibility in pharmaceutical companies, including more than ten
years at Amgen Inc. M r. Pätsi began his career as a Biomedical
Research Scientist in Finland. He is a registered pharmacist and
holds an MSc in pharmacology from the School of Pharmacy, Helsinki
University.
Additional Disclosures
The following information regarding the appointment of Tuomo
Tapani Pätsi (aged 58), is disclosed under Schedule 2(g) of the AIM
Rules for Companies and Nasdaq First North Growth Market
Rulebook.
Current positions, directorships Former positions, directorships
and/or partnerships: and/or partnerships (within the
last five years):
Celgene
Celgene ApS
Celgene BV
Celgene Distribution BV
Celgene EngMab GmbH
Celgene Europe BV
Celgene Europe Limited
Celgene Global Holdings Sàrl
Celgene GmbH
Celgene International II Sàrl
Celgene International III Sàrl
Celgene International Sàrl
Celgene Limited
Celgene Logisitics Sarl
Celgene Logistics Sàrl
Celgene Management Sàrl
Celgene Netherlands BV
Celgene Netherlands II BV
Celgene Netherlands Investment
BV
Celgene R&D Sàrl
Celgene Receptos Limited
Celgene Receptos Sàrl
Celgene Research SL
Celgene SL
Celgene Spó ka SOO
Celgene sro
Celgene Switzerland Sàrl
Celgene Tri Sàrl
EngMab Sàrl
Interpharma
Juno Therapeutics GmbH
Mr. Pätsi does not have any beneficial interest in the ordinary
shares or options over the ordinary shares of the Company.
Save as set out above, no further information regarding Mr.
Pätsi is required to be disclosed pursuant to the AIM Rules for
Companies or Nasdaq First North Growth Market Rulebook.
For more information please contact:
Media Contact
Faron Pharmaceuticals
Faron Pharmaceuticals
Jennifer C. Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)
together with its subsidiaries, is a clinical stage
biopharmaceutical group focused on building the future of
immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation. Bexmarilimab, a novel anti-CLEVER-1
humanized antibody, is its investigative precision immunotherapy
with the potential to provide permanent immune stimulation for
difficult-to-treat cancers through targeting myeloid function.
Currently in Phase I/II clinical development as a potential therapy
for patients with hematological cancers and untreatable solid
tumors, bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. In terms of other pipeline assets,
Traumakine(R) is an investigational intravenous (IV) interferon
beta-1a therapy for the treatment of hyperinflammatory conditions.
Faron is headquartered in Turku, Finland. Further information is
available at www.faron.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUBUWUPWGWC
(END) Dow Jones Newswires
March 24, 2023 09:35 ET (13:35 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024